TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28659614

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) applied for 10 minutes to the more affected motor cortex.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) ON medication.
Number of subjects: 0
Study: 26309023

Group type: COMPARATOR
Intervention: Rapid Diagnostic Tests (RDTs) with basic instruction (control)
Number of subjects: 4946

Group type: EXPERIMENTAL
Intervention: RDTs with provider training (provider arm)
Number of subjects: 4946

Group type: EXPERIMENTAL
Intervention: RDTs with provider training plus a school‐based community intervention (provider‐school arm)
Number of subjects: 4946
Study: 24339699

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Infliximab treatment during the extension study
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Infliximab and methotrexate
Number of subjects: 143
Study: 21385988

Group type: EXPERIMENTAL
Intervention: Rolapitant 20 mg
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Rolapitant 70 mg
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Rolapitant 200 mg
Number of subjects: 619

Group type: COMPARATOR
Intervention: Ondansetron 4 mg (active control)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 17653859

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 16813478

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) applied to the gastrocnemius‐soleus muscle complex for 15 trials
Number of subjects: 13

Group type: COMPARATOR
Intervention: No functional electrical stimulation (no FES) for 15 trials
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No functional electrical stimulation (no FES)
Number of subjects: 13
Study: 12677608

Group type: EXPERIMENTAL
Intervention: Modified soft drink
Number of subjects: 15

Group type: COMPARATOR
Intervention: Original soft drink
Number of subjects: 15
Study: 10729389

Group type: EXPERIMENTAL
Intervention: High saturated fat diet (21% energy from saturated fat, 3% energy from polyunsaturated fat)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High polyunsaturated fat diet (11% energy from saturated fat, 10% energy from polyunsaturated fat)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Apo AIV Q/H individuals (n=6)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Apo AIV Q/Q individuals
Number of subjects: 46
Study: 9014006

Group type: EXPERIMENTAL
Intervention: Inactivated combined vaccine (ICV) against Q fever
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1547611

Group type: EXPERIMENTAL
Intervention: Bi-annual topical APF gel applications
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study: 2860494

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tri-potassium di-citrato bismuthate (TDB) tablet four times a day
Number of subjects: 120
Study: 30672127

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-Reported Energy Intake (∆EIRecall)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective Energy Intake (∆EIModel)
Number of subjects: 0
Study: 28801122

Group type: EXPERIMENTAL
Intervention: Serum deoxycholic acid concentration > 58ng/mL
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Baseline deoxycholic acid concentrations
Number of subjects: 112
Study: 27570866

Group type: COMPARATOR
Intervention: NICE guidelines
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: MPS
Number of subjects: 1202
Study: 24907195

Group type: EXPERIMENTAL
Intervention: Surgery group (skin grafting)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 200
Study: 22614394

Group type: EXPERIMENTAL
Intervention: Touch with a soft elastomer brush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Touch with a flat disc
Number of subjects: 0
Study: 20705902

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg) with paroxetine (10 mg orally twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carvedilol (12.5 mg) without paroxetine
Number of subjects: 12
Study: 17403578

Group type: EXPERIMENTAL
Intervention: Intradermal injection of ET-1 (concentrations ranging from 10(‐10) to 10(‐6)M)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 35
Study: 15384455

Group type: EXPERIMENTAL
Intervention: Perpetration of domestic assault by a man
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Perpetration of domestic assault by an African American perpetrator
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Women who assault their husbands
Number of subjects: 503
Study: 11295415

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250mg bid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300mg bid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Ofloxacin
Number of subjects: 40
Study: 10205329

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (BENEFIBER)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Liquid formula diet without fibre
Number of subjects: 10
Study: 7960618

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.5 mmol/kg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.04, 0.1, 0.4 mmol/kg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gadobutrol (various doses)
Number of subjects: 91
Study: 3302916

Group type: EXPERIMENTAL
Intervention: Immediate penicillin treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed treatment (48 to 56 hours)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment (aspirin or acetaminophen)
Number of subjects: 142
Study: 31512155

Group type: EXPERIMENTAL
Intervention: Telephone and text message support in addition to standard OMS care
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard OMS care alone
Number of subjects: 61
Study: 29407564

Group type: EXPERIMENTAL
Intervention: Response Inhibition Training (RIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waitlisted Control (WLT)
Number of subjects: 22
Study: 27373755

Group type: EXPERIMENTAL
Intervention: Fortified peanut butter paste
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Food purchasing at school
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Consumption of fish
Number of subjects: 968
Study: 24022677

Group type: EXPERIMENTAL
Intervention: Yearly Family Check-Ups (FCUs)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 731
Study: 22042749

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg per day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 400 µg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Eosinophils in peripheral blood
Number of subjects: 50
Study: 20705534

Group type: EXPERIMENTAL
Intervention: MK‐8141 250 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MK‐8141 500 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 17569711

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.60 mg/kg of body weight
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 15730599

Group type: EXPERIMENTAL
Intervention: Theophylline plus placebo (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terbutaline plus placebo (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Theophylline and terbutaline together (group 3)
Number of subjects: 40
Study: 11899738

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10567626

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (100 mg)
Number of subjects: 16
Study: 8918323

Group type: EXPERIMENTAL
Intervention: 200 IU/kg once-daily dalteparin (group 1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 100 IU/kg twice-daily dalteparin (group 2)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 140
Study: 1717341

Group type: COMPARATOR
Intervention: Nd:YAG laser recanalization alone (N = 20)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Laser recanalization and subsequent endoluminal afterloading irradiation with iridium-192 at a dose of 3 x 7 Gy (6 x 7 Gy)
Number of subjects: 39
Study: 6749604

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (30 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (30 g) for longer periods (5 to 22 weeks)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Number of subjects: 7
Study: 31377925

Group type: EXPERIMENTAL
Intervention: Centralized virtual reading center interpretation
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Pre-centralization interpretation by ophthalmologists
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Post-centralization interpretation by optometrists
Number of subjects: 1902
Study: 30352291

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention including an in-person educational session, an informative leaflet, and two phone-based sessions at 1 and 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention.
Number of subjects: 0
Study: 27612281

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC
Number of subjects: 0
Study: 26257021

Group type: EXPERIMENTAL
Intervention: Double-dose (40 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard-dose (20 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Double-dose (40 μg) group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard-dose (20 μg) group
Number of subjects: 178
Study: 24979519

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% eyedrops
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 62
Study: 22435114

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 50
Study: 19397693

Group type: EXPERIMENTAL
Intervention: Fluvastatin/fenofibrate (80/200 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Simvastatin/ezetimibe (20/10 mg)
Number of subjects: 75
Study: 17321817

Group type: EXPERIMENTAL
Intervention: Motorized scooter for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Motorized scooter usage
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Accidents while using the scooter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Scooter usage in diverse locations
Number of subjects: 22
Study: 15114043

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TCM group, n = 27)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control treatment at non-acupuncture points (control group, n = 24)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TCM group)
Number of subjects: 51
Study: 10831139

Group type: EXPERIMENTAL
Intervention: Pathological attachment measure (compulsive care-seeking, angry withdrawal, compulsive self-reliance)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Attachment pathology and insecure attachment style
Number of subjects: 209
Study: 9113548

Group type: EXPERIMENTAL
Intervention: Midvastus muscle-splitting approach
Number of subjects: 118

Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 118
Study: 7508973

Group type: EXPERIMENTAL
Intervention: Anti-HCV positive patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HBsAg positive patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HBsAg carriers
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HBsAg alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anti-HCV alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both HBsAg and anti-HCV positive
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Population-attributable risk for anti-HCV alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Population-attributable risk for HBsAg alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Population-attributable risk for both anti-HCV and HBsAg
Number of subjects: 150
Study: 2993687

Group type: EXPERIMENTAL
Intervention: Guar gum (5 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2451578

Group type: EXPERIMENTAL
Intervention: 10 ml dextran 70 in saline solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 ml saline solution (control)
Number of subjects: 10
Study: 30181338

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (10 IU in 1 mL given slowly over one minute)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU in 1 mL)
Number of subjects: 1075
Study: 28898104

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided barbotage combined with a subacromial corticosteroid injection (SAIC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isolated ultrasound-guided SAIC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 26399868

Group type: EXPERIMENTAL
Intervention: Overfeeding (+50% of energy needs for 1 week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR, -50% of energy needs for 3 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Refeeding (+50% of energy needs for 2 weeks)
Number of subjects: 32
Study: 24617124

Group type: EXPERIMENTAL
Intervention: Yoga intervention (35-40 min/day, 5 days a week for 18 months)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non-yoga group (control)
Number of subjects: 258
Study: 21428979

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied twice daily for 7 days before photoprovocation testing
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 7 days before photoprovocation testing
Number of subjects: 13
Study: 19278080

Group type: EXPERIMENTAL
Intervention: Baking soda dentifrice
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Baking soda dentifrice (single brushing)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Triclosan dentifrice
Number of subjects: 207

Group type: COMPARATOR
Intervention: Triclosan dentifrice (single brushing)
Number of subjects: 207
Study: 17136289

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with proton pump inhibitors for GERD symptoms and esophageal injury.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for GERD when esophageal symptoms are absent.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of pharmacological treatment for GERD.
Number of subjects: 0
Study: 12920409

Group type: EXPERIMENTAL
Intervention: Rapid initial dose escalation (RIDE) of up to 40 mg of oral olanzapine on days 1 and 2, up to 30 mg on days 3 and 4, and 5 to 20 mg thereafter
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual clinical practice (UCP) with 10 mg/d olanzapine plus up to 4 mg lorazepam on days 1 and 2, up to 2 mg on days 3 and 4, and olanzapine 5 to 20 mg/d thereafter
Number of subjects: 148
Study: 10870534

Group type: EXPERIMENTAL
Intervention: Management guided by a clinical pathway (55 patients)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Established standard of care (control group, 56 patients)
Number of subjects: 111
Study: 9292632

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg) administered on days 2 and 11
Number of subjects: 7

Group type: COMPARATOR
Intervention: No capsule administered on days 1 and 9
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo administered on days 3 and 10
Number of subjects: 7
Study: 8385974

Group type: EXPERIMENTAL
Intervention: 0.01 mg kg‐1 intravenously (i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 intravenously (i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 orally (p.o.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.03 mg kg‐1 intravenously (i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 intravenously (i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 orally (p.o.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg‐1 orally (p.o.) and 0.3 mg kg‐1 orally (p.o.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous dosing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 3519094

Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of ketoprofen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard formulation of ketoprofen
Number of subjects: 8
Study: 30635020

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg orally three times a day
Number of subjects: 360
Study: 29554173

Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet (daily for 2 weeks, then twice weekly) plus placebo gel (3 times a week)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 302

Group type: COMPARATOR
Intervention: Dual placebo (placebo tablet plus vaginal gel)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet
Number of subjects: 302
Study: 27189156

Group type: EXPERIMENTAL
Intervention: Short-tip cryoballoon (ST CB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Advance cryoballoon (ADV CB)
Number of subjects: 64
Study: 25605283

Group type: EXPERIMENTAL
Intervention: Clofazimine (Cfz) therapy group (n = 53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (n = 52)
Number of subjects: 105
Study: 23046862

Group type: EXPERIMENTAL
Intervention: Phaseolus vulgaris extract (PVE) 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21964222

Group type: EXPERIMENTAL
Intervention: PLISSIT model sexual program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 22073466

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional osteotomies (CO)
Number of subjects: 0
Study: 16983393

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily for 2 years)
Number of subjects: 161
Study: 12826249

Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel with external beam radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel and gemcitabine with RT followed by R115777
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional postoperative chemoirradiation (5‐fluorouracil before, after, and during RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine given concurrently with RT
Number of subjects: 0
Study: 11232071

Group type: EXPERIMENTAL
Intervention: Educational intervention based on audit and feedback with opportunity for reflection on practice
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 46
Study: 9355184

Group type: EXPERIMENTAL
Intervention: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (fellow eye in Group 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 2)
Number of subjects: 46
Study: 8471778

Group type: EXPERIMENTAL
Intervention: FTBI/VP‐16
Number of subjects: 122

Group type: COMPARATOR
Intervention: BU/CY
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CSA/PSE
Number of subjects: 122
Study: 3016111

Group type: EXPERIMENTAL
Intervention: Intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30129268

Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush and conventional toothbrush combination (Group 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush (Group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional toothbrush (Group 1)
Number of subjects: 20
Study: 28028253

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration, with a recommended dose of IP PTX being 20 mg/m2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration for P1 gastric cancer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy (IP chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of docetaxel
Number of subjects: 0
Study: 26061040

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring for HIV-1 prevention
Number of subjects: 2629

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2629
Study: 23929781

Group type: EXPERIMENTAL
Intervention: Anemia (defined as baseline Hb <13 g/dL in men and <12 g/dL in women)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 2331
Study: 20575281

Group type: COMPARATOR
Intervention: Trapezoid compression plate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Anatomic plate
Number of subjects: 57